Top 10 Breast Cancer Articles of 2018

Top 10 Breast Cancer Articles of 2018
Breast Cancer News brought you daily coverage of important discoveries, treatment developments, clinical trials, and other events dealing with breast cancer throughout 2018. As a reminder of what mattered most to our readers in 2018, here are the 10 most-read articles of last year, with a brief description of what made them interesting and relevant to breast cancer patients, family members, and caregivers. No. 10 – "Patient Dosing Begins in Phase 2 Trial of MCLA-128 in Metastatic Breast Cancer" In February, Merus opened an international Phase 2 clinical trial (NCT03321981) to explore its investigational antibody MCLA-128 as treatment for patients with HER2-positive or hormone receptor-positive/HER2-low metastatic breast cancer. The ongoing trial is enrolling at sites in the U.S. and Europe, and aims to include 120 women to explore combinations of MCLA-128 with Herceptin (trastuzumab, by Genentech) plus chemotherapy or with endocrine therapy. No. 9 – "Ibrance-Faslodex Combo Improves Survival of Advanced Breast Cancer Patients, Phase 3 Trial Shows" Patients with advanced breast cancer who no longer respond to hormone therapy seem to benefit from a combination of Faslodex (fulvestrant, by AstraZeneca) plus the CDK4/6 inhibitor Ibrance (palbociclib, by Pfizer), data from the PALOMA-3 Phase 3 trial (NCT01942135) showed. In this study, which included 521 patients with advanced hormone receptor-positive/HER2-negative breast cancer, the treatment combination (compared to Faslodex and placebo) extended survival from 28 to 34.9 months, and nearly doubled the time until chemotherapy was necessary — to 17.6 months versus 8.8 months. No. 8 – "Radiation to Lymph Nodes in Chest Seen to Improve Breast Cancer Outcomes at 15 Years with Little Added Risk" A gr
Subscribe or to access all post and page content.